https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/funding-success-parkinson-s-research/
Funding success for Parkinson’s research
24 Sep 2020, 1 p.m.
Two multi-million-pound research grants will fund a pioneering new programme of research aimed at understanding and tackling Parkinson’s disease, including vital genetic investigations at the UCL Great Ormond Street Institute of Child Health (ICH).
While the root cause of Parkinson’s is still poorly understood, it is clear that certain genetic factors increase the risk of developing the disease and can be passed on between generations. With world-renowned expertise in the discovery, diagnosis and interpretation of genetic syndromes that affect children, the ICH/UCL Genomics team are ideally placed to contribute to these studies.
Getting to the root of Parkinson's
Totalling more than $14 million (more than £10 million), the awards for global research initiative Aligning Science Across Parkinson's will help researchers understand the root cause of Parkinson’s, why the condition progresses so quickly in some patients but not others, and how we might slow its devastating effects.
Dr Mina Ryten, Professor of Clinical Genetics at the ICH and member of the National Institute of Health Research (NIHR) Great Ormond Street Hospital Biomedical Research Centre (BRC) Genomics and Systems Medicine theme, will provide genetic expertise for the project by analysing adult brain tissue to understand the mechanisms underlying Parkinson’s disease.
‘This research could make a real difference to families who currently face an uncertain and difficult future after a Parkinson’s diagnosis,’ says Professor Ryten. ‘As specialists in rare and complex childhood conditions, many of which have a genetic root cause, our team at GOSH has the expertise to carry out detailed genetic sequencing and molecular analysis. I hope these studies will also provide useful data for degenerative brain disorders affecting children, as well as important methods and analyses that could be applied to our work in paediatrics.’
Studying cells to map the brain
The grants will provide approximately £1.5 million for three years of genetic research at the ICH, with much of the analysis taking place in the Zayed Centre for Research into Rare Disease in Children. This newly opened centre is a partnership between Great Ormond Street Hospital (GOSH), University College London (UCL) and Great Ormond Street Hospital Children’s Charity (GOSH Charity).
The ICH team will study individual brain cells taken from adults during the early stages of Parkinson’s. They will look at the genetic instructions inside these cells and how the instructions are interpreted by the body. This could reveal key genes and processes that are responsible for the most severe symptoms of Parkinson’s, as well as why it progresses so quickly in some patients but not others.
The research team hope to produce the first open-access map of the Parkinson’s brain, including the genes and cell pathways that most influence its progress. This unique resource will support the research community to better understand the condition and, crucially, develop new ways of tackling its devastating effects.
Read more on the UCL website.

Young people donate tissue samples to unlock mysteries of arthritis
A new groundbreaking study led by researchers at the University of Birmingham, Great Ormond Street Hospital, University College London and Birmingham Children’s Hospital has revealed important clues into what is driving arthritis in children.

Toddler doing well after receiving newest gene therapy available on NHS
A toddler with a life-limiting and life-threatening rare disease is the youngest to be treated with the newest gene therapy available on the NHS at GOSH.

Genes may help to predict which children will respond well to arthritis treatment
A team of researchers at Great Ormond Street Hospital (GOSH) and University College London (UCL) have identified a set of genes that could be used to help doctors predict which children will respond well to treatment for juvenile idiopathic arthritis.

Making it easier to invest in frontline care
GOSH and UCL have signed a landmark agreement to simplify the commercialisation of any joint research and innovation and ensure any financial proceeds are shared equally.